Synmosa Biopharma Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
Synmosa Biopharma Fair Value Forecast for 2023 - 2025 - 2030
Synmosa Biopharma's Price has decreased In the last three years, from NT$75.40 to NT$0.00 – a 100.00% drop. For next year, analysts predict Fair Value of NT$0.00, which would mean an increase of 100.00%. Over the next six years, experts predict that Synmosa Biopharma's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1795 Stock Forecast | Lotus Pharmaceutical | Buy |
16
|
NT$314.50 | Buy/Sell | NT$339.40 | 9.38% |
| 6472 Stock Forecast | Bora Pharmaceuticals Co., LTD. | Outperform |
15
|
NT$752.00 | Buy/Sell | NT$703.67 | 13.03% |
| 4123 Stock Forecast | Center Laboratories | - |
10
|
NT$46.70 | Buy/Sell | NT$0.00 | -100.00% |
| 1789 Stock Forecast | ScinoPharm Taiwan | Hold |
18
|
NT$28.15 | Buy/Sell | NT$26.00 | -7.64% |
| 4105 Stock Forecast | TTY Biopharm Company | Hold |
18
|
NT$76.60 | Buy/Sell | NT$86.00 | 12.92% |
Synmosa Biopharma Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Synmosa Biopharma's Revenue has grown by 44.37%, rising from NT$3.04B to NT$4.39B. In the following year, 0 experts forecast Synmosa Biopharma's Revenue will decrease by 19.53%, to NT$3.53B. In 2030, professionals predict that Synmosa Biopharma's Revenue will decrease by 17.55%, to NT$3.62B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 6620 Stock Forecast | Handa Pharmaceuticals | Buy |
4
|
NT$130.50 | Buy/Sell | NT$200.00 | 53.26% |
| 8436 Stock Forecast | TCI | Hold |
16
|
NT$145.50 | Buy/Sell | NT$185.20 | 16.84% |
| 6576 Stock Forecast | Foresee Pharmaceuticals | Buy |
6
|
NT$95.00 | Buy/Sell | NT$122.25 | 61.05% |
.jpg)
Synmosa Biopharma Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Synmosa Biopharma's Dividend per Share has grown, rising from NT$0.27 to NT$0.51 – a growth of 88.89%. According to 0 major analysts, Synmosa Biopharma's Dividend per Share will fall by 20.30% in the next year, reaching NT$0.41. Professionals believe that By 2030, Synmosa Biopharma's Dividend per Share will fall to NT$0.42– a 17.99% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 6586 Stock Forecast | CHO Pharma | - |
6
|
NT$55.20 | Buy/Sell | NT$0.00 | -100.00% |
| 3705 Stock Forecast | YungShin Global Holding | - |
18
|
NT$46.70 | Buy/Sell | NT$0.00 | -100.00% |
| 4119 Stock Forecast | SCI Pharmtech | - |
18
|
NT$89.00 | Buy/Sell | NT$116.44 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1760 Stock Forecast | Panion & Bf Biotech | - |
16
|
NT$96.50 | Buy/Sell | NT$102.00 | -100.00% |
| 1701 Stock Forecast | China Chemical & Pharmaceutica... | - |
16
|
NT$23.60 | Buy/Sell | NT$0.00 | -100.00% |
| 3266 Stock Forecast | Sunty Development Co., LTD | - |
15
|
NT$20.95 | Buy/Sell | NT$0.00 | -100.00% |
Synmosa Biopharma EBITDA Forecast for 2023 - 2025 - 2030
Synmosa Biopharma's EBITDA has seen impressive growth In the last two years, rising from NT$437.99M to NT$760.78M – a growth of 73.70%. According to 0 analysts, Synmosa Biopharma's EBITDA will fall by 27.59% in the next year, reaching NT$550.86M. Professionals believe that By 2030, Synmosa Biopharma's EBITDA will fall to NT$582.01M – a 23.50% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 6575 Stock Forecast | SyneuRx International (Taiwan) | - |
9
|
NT$48.95 | Buy/Sell | NT$0.00 | -100.00% |
| 1734 Stock Forecast | Sinphar Pharmaceutical | - |
8
|
NT$36.65 | Buy/Sell | NT$24.00 | -100.00% |
| 6634 Stock Forecast | Sinew Pharma | - |
7
|
NT$57.80 | Buy/Sell | NT$0.00 | -100.00% |
Synmosa Biopharma EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Synmosa Biopharma's EBIT has grown by 208.15%, rising from NT$149.51M to NT$460.71M. In the following year, 0 experts forecast that Synmosa Biopharma's EBIT will decrease by 46.29%, to NT$247.43M. In 2030, professionals predict that Synmosa Biopharma's EBIT will decrease by 33.56%, to NT$306.08M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 6657 Stock Forecast | Energenesis Biomedical CO.,LTD... | - |
8
|
NT$54.80 | Buy/Sell | NT$0.00 | -100.00% |
| 4108 Stock Forecast | PhytoHealth | - |
4
|
NT$19.80 | Buy/Sell | NT$36.50 | -100.00% |
| 4166 Stock Forecast | Orient Pharma | - |
4
|
NT$20.55 | Buy/Sell | NT$0.00 | -100.00% |
Synmosa Biopharma EPS Price Prediction Forecast for 2023 - 2025 - 2030
Synmosa Biopharma's EPS has decreased In the last three years, from NT$1.82 to NT$0.00 – a 100.00% drop. For next year, analysts predict EPS of NT$0.00, which would mean an increase of 100.00%. Over the next six years, experts predict that Synmosa Biopharma's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1752 Stock Forecast | Nang Kuang Pharmaceutical | - |
18
|
NT$48.40 | Buy/Sell | NT$0.00 | -100.00% |
| 6461 Stock Forecast | Intech Biopharm | - |
5
|
NT$30.80 | Buy/Sell | NT$0.00 | -100.00% |
| 1762 Stock Forecast | Chunghwa Chemical Synthesis & ... | Hold |
16
|
NT$44.90 | Buy/Sell | NT$70.00 | 6.90% |
.jpg)